OurGLP1 archive
Page 3 of carefully sourced research, regulatory, safety and availability reporting.
Latest GLP-1 news3 August 2026
We examine the anatomy behind apparent changes in penile length, the unsupported 1–2 inch claim, and conflicting evidence about semaglutide and erectile function.
Read the sourced summary2 August 2026
GLP-1 and related medicines now have defined cardiovascular, kidney, MASH and sleep-apnoea uses. We separate those approvals from early research and a negative Alzheimer’s programme.
Read the sourced summary31 July 2026
EMA, MHRA and FDA reviews have not found evidence that GLP-1 medicines increase suicidal thoughts or behaviour. We explain the findings, their limits and why individual experiences still matter.
Read the sourced summary30 July 2026
Oura's GLP-1 Insights combines logged doses, side effects and weight with wearable trends. Here is what the product does, how Lilly is involved and what has not yet been demonstrated.
Read the sourced summary29 July 2026
A careful look at the limited evidence on GLP-1 medicines, sexual desire and relationships, including a randomised dulaglutide trial and an FDA adverse-event database analysis.
Read the sourced summary29 July 2026
A Phase 2 apitegromab study and several registered trials show why obesity-drug research is looking beyond kilograms lost to lean mass, strength and physical function.
Read the sourced summary29 July 2026
A sourced roundup of new Retatrutide Phase 3 results, the US approval of oral orforglipron, Australian NAION warnings and an observational alcohol-hospitalisation study.
Read the sourced summary